Eledon Pharmaceuticals, Inc. (ELDN) Form 10-Q — May 13, 2026
Eledon Pharmaceuticals, Inc. reported a net loss of $39.0 million for the three months ended March 31, 2026, reflecting ongoing significant operating losses. The company's cash and cash equivalents and short-term investments as of March 31, 2026, were $111.1 million, down from $132.2 million as of December 31, 2025. This decrease is primarily due to the net loss and the change in fair value of warrant liabilities, which increased by $19.0 million.
Key figures
- Eps
- 0
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -39,025
- Total Debt
- 46,209
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 146,667
- Cash Position
- 111,100
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 77,187,823
- Warrant Liabilities
- 30,378
Price after filing
1 day: +1.8%7 days: -1.0%30 days: -8.0%
Close on the filing date to close N calendar days later (from $3.88). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.